ZGNX - Zogenix's Fintepla shows improved executive function in rare severe epilepsy

Zogenix (ZGNX) announces new data showing the positive impact of treatment with Fintepla (fenfluramine) oral solution on everyday executive function for children and young adults with Lennox-Gastaut syndrome ((LGS)), a rare, severe epilepsy. Treatment continued for a combined 14-week titration and maintenance period and included 137 patients (age 6-18). More patients on Fintepla than placebo showed improvement in each of the four BRIEF 2 indexes (Behavior, Emotions, Cognition, and Global Executive Composite).Improvement was significantly greater for the BRI (Behavior) (24% vs. 13% placebo, p=0.118); CRI (Cognition) (27% vs 13% placebo, p=0.046); and GEC (Global Executive Composite) (25% vs 11% placebo, p=0.034) scores, indicating clinically meaningful improvement in the Fintepla-treated patients.Subjects with greater improvement in seizure control were more likely to show clinically meaningful improvements in executive functioning after the 14-week study duration.The data was presented at the American Academy of Neurology ((AAN)) Meeting this week.

For further details see:

Zogenix's Fintepla shows improved executive function in rare, severe epilepsy